The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Ebola

Ebola virus causes a viral haemorrhagic fever in humans and other primates. The disease has a high mortality rate, killing between 25-90% of those infected, with an average mortality rate of 50%. Since a significant outbreak in West Africa, in 2014/15, there have been further sporadic outbreaks, leading to continued concern about re-emergence.

The Native Antigen Company offer a range of recombinant Ebola proteins and antibodies to support research into this disease.

Ebola Background

Ebola virus disease (EVD) is a severe illness caused by several species of Ebolavirus (EBOV), of the family Filoviridae. Prior to 2007, four species of EBOV had been identified, with two (Zaire ebolavirus and Sudan ebolavirus) having caused large outbreaks in humans. The presence of a fifth EBOV species, Bundibugyo ebolavirus (BDBV) was identified after an outbreak of EVD in the Bundibugyo district of western Uganda in 2007. Outbreaks of EVD are associated with person-to-person transmission after the virus is introduced to human populations from its zoonotic reservoir. During outbreaks, the virus is commonly transmitted through direct contact with infected persons or their bodily fluids. The onset of EVD is associated with nonspecific clinical symptoms, including fever, myalgia, headache, abdominal pain, nausea, vomiting, and diarrhoea. In the later stages of disease, overt haemorrhage has been reported in up to 50% of cases.

The Zaire subtype of the EBOV family is currently the most significant in relation to outbreaks of disease in humans. This subtype was responsible for the largest ever outbreak of EVD, which started in West Africa in 2014 and was finally declared over only in early 2016.

References

  1. Adam MacNeil et al (2010). Proportion of Deaths and Clinical Features in Bundibugyo Ebola Virus Infection, Uganda. Emerg Infect Dis. 16(12): 1969–1972.

Ebola Antigens

The Native Antigen Company supply highly purified viral antigens, developed using our proprietary mammalian expression system to support researchers working with EBOV. Our range includes envelope glycoproteins from both Zaire and Bundibugyo strains and Ebola VLPs, which contain nucleoprotein, glycoprotein and VP40 antigens.

Ebola Antibodies

To complement our range of Ebola virus antigens. we are pleased to offer a range of monoclonal and polyclonal antibodies, specific to Ebola virus proteins. These include antibodies that are specific to Ebola nucleoprotein and VP40 antigens.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Monkeypox; 3 months on

It has been 3 months since a new, unusually widespread outbreak of Monkeypox was first identified. What was normally a virus confined to limited infections in the West African continent is becoming a global health concern.   What have we learned about this virus...

COVID-19 Underlines the Need for Universal Vaccines

This article was originally published on Clinical Lab Manager. In recent history, humanity has witnessed numerous emerging viral diseases, including the SARS, MERS, and SARS-2 coronaviruses, as well as HIV, Zika, Ebola, and H1N1 and H3N2 influenza. None have tested...

Tick-Borne Diseases: The Need for Integrated Approaches to Human-Animal Diagnosis

This article has been published in Volume 8, Issue 3 of International Animal Health Journal. Ticks are responsible for a diverse group of neglected, and rapidly expanding diseases, affecting humans, companion animals and livestock. A growing understanding of tick-host...

The Continued Challenges of Flavivirus Serology

This article was originally published on the Science Advisory Board. Flaviviruses are a genus of positive-sense RNA viruses, largely transmitted by mosquito and tick vectors that cause infections, including yellow fever, dengue, the Zika virus, West Nile virus,...

The Role of Serology in Tracking COVID-19 Mutations

This article was originally published on Clinical Lab Products. As SARS-CoV-2 began its global proliferation in early 2020, scientists hastened to investigate its biology, develop diagnostic tests, and design candidate vaccines, marking one of the most...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

11 + 3 =